| Literature DB >> 26989201 |
Jane A Healy1, Adrienne Nugent1, Rachel E Rempel1, Andrea B Moffitt1, Nicholas S Davis1, Xiaoyu Jiang2, Jennifer R Shingleton1, Jenny Zhang1, Cassandra Love1, Jyotishka Datta3, Matthew E McKinney1, Tiffany J Tzeng1, Nina Wettschureck4, Stefan Offermanns4, Katelyn A Walzer5, Jen-Tsan Chi5, Suhail A K Rasheed6, Patrick J Casey6, Izidore S Lossos2, Sandeep S Dave1.
Abstract
GNA13 is the most frequently mutated gene in germinal center (GC)-derived B-cell lymphomas, including nearly a quarter of Burkitt lymphoma and GC-derived diffuse large B-cell lymphoma. These mutations occur in a pattern consistent with loss of function. We have modeled the GNA13-deficient state exclusively in GC B cells by crossing the Gna13 conditional knockout mouse strain with the GC-specific AID-Cre transgenic strain. AID-Cre(+) GNA13-deficient mice demonstrate disordered GC architecture and dark zone/light zone distribution in vivo, and demonstrate altered migration behavior, decreased levels of filamentous actin, and attenuated RhoA activity in vitro. We also found that GNA13-deficient mice have increased numbers of GC B cells that display impaired caspase-mediated cell death and increased frequency of somatic hypermutation in the immunoglobulin VH locus. Lastly, GNA13 deficiency, combined with conditional MYC transgene expression in mouse GC B cells, promotes lymphomagenesis. Thus, GNA13 loss is associated with GC B-cell persistence, in which impaired apoptosis and ongoing somatic hypermutation may lead to an increased risk of lymphoma development.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26989201 PMCID: PMC4991089 DOI: 10.1182/blood-2015-07-659938
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113